Published in Transplantation on February 15, 2010
Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther (2012) 1.19
A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med (2014) 1.10
Insulin-producing cells from adult human bone marrow mesenchymal stem cells control streptozotocin-induced diabetes in nude mice. Cell Transplant (2012) 0.98
Mesenchymal stem cell therapy in diabetes mellitus: progress and challenges. J Nucleic Acids (2013) 0.88
Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. Front Immunol (2012) 0.85
A new home for pancreatic islet transplants: the bone marrow. Diabetes (2013) 0.77
Mesenchymal Stromal Cells as a Therapeutic Strategy to Support Islet Transplantation in Type 1 Diabetes Mellitus. Cell Med (2011) 0.75
Genetically engineered islets and alternative sources of insulin-producing cells for treating autoimmune diabetes: quo vadis? Int J Endocrinol (2012) 0.75
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med (2000) 18.26
International trial of the Edmonton protocol for islet transplantation. N Engl J Med (2006) 13.43
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood (2002) 9.40
Immunomodulatory properties of mesenchymal stromal cells. Blood (2007) 6.97
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med (2006) 6.71
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood (2005) 5.82
Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12
Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood (2005) 4.10
IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol (2008) 3.53
Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood (2006) 3.16
Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum (2007) 3.08
Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 2.17
Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol (2006) 2.16
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol (2009) 2.15
Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes (2009) 1.78
The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells (2008) 1.77
Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest (2008) 1.73
Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One (2008) 1.67
Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells (2008) 1.58
Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol (2008) 1.49
Mesenchymal stem cells: a potential border patrol for transplanted islets? Diabetes (2009) 0.93
Donor reactive regulatory T cells. Curr Opin Organ Transplant (2009) 0.90
Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest (2010) 3.41
CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol (2002) 3.41
A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol (2004) 2.39
Mechanisms of rejection: current perspectives. Transplantation (2012) 2.19
Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell (2010) 2.10
IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med (2005) 2.07
In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med (2010) 2.01
Regulatory immune cells in transplantation. Nat Rev Immunol (2012) 1.82
Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A (2007) 1.81
Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes (2009) 1.78
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol (2010) 1.72
Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol (2004) 1.59
Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: implications for anti-CD154 immunotherapy. J Immunol (2002) 1.59
Production and implantation of renal extracellular matrix scaffolds from porcine kidneys as a platform for renal bioengineering investigations. Ann Surg (2012) 1.45
Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant (2004) 1.40
Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol (2008) 1.36
The impact of memory T cells on rejection and the induction of tolerance. Transplantation (2006) 1.34
Regenerative medicine as applied to solid organ transplantation: current status and future challenges. Transpl Int (2010) 1.33
Impact of hepatic rearterialization on reperfusion injury and outcome after mouse liver transplantation. Transplantation (2003) 1.31
Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol (2006) 1.28
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
Moving to tolerance: clinical application of T regulatory cells. Semin Immunol (2011) 1.25
Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy. Transplantation (2008) 1.22
Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int J Biochem Cell Biol (2008) 1.18
Regenerative medicine and organ transplantation: past, present, and future. Transplantation (2011) 1.14
Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation (2006) 1.14
Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells. J Immunol (2008) 1.09
Role of T cells in graft rejection and transplantation tolerance. Expert Rev Clin Immunol (2010) 1.08
The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant (2010) 1.07
Effector and memory CD8+ T cells can be generated in response to alloantigen independently of CD4+ T cell help. J Immunol (2006) 1.07
Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells (2008) 1.07
Transplanting stem cells: potential targets for immune attack. Modulating the immune response against embryonic stem cell transplantation. Adv Drug Deliv Rev (2005) 1.03
Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection? Transplantation (2007) 1.03
Immunomodulatory effect of a decellularized skeletal muscle scaffold in a discordant xenotransplantation model. Proc Natl Acad Sci U S A (2013) 1.03
Regulatory T cells in transplantation: transferring mouse studies to the clinic. Transplantation (2009) 1.02
Th17: contributors to allograft rejection and a barrier to the induction of transplantation tolerance? Transplantation (2011) 1.00
Embryonic stem cell transplantation: potential applicability in cell replacement therapy and regenerative medicine. Front Biosci (2007) 1.00
Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci Transl Med (2011) 0.99
In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One (2010) 0.99
Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells. Transplantation (2010) 0.96
Costimulation blockade: current perspectives and implications for therapy. Transplantation (2013) 0.95
Anti-CD4-mediated selection of Treg in vitro - in vitro suppression does not predict in vivo capacity to prevent graft rejection. Eur J Immunol (2008) 0.95
Chemokine gene expression during allograft rejection: comparison of two quantitative PCR techniques. J Immunol Methods (2005) 0.95
Pretransplant blood transfusion without additional immunotherapy generates CD25+CD4+ regulatory T cells: a potential explanation for the blood-transfusion effect. Transplantation (2003) 0.95
Transplantation tolerance: lessons from experimental rodent models. Transpl Int (2007) 0.94
Immunogenicity of embryonic stem cell-derived progenitors after transplantation. Curr Opin Organ Transplant (2011) 0.94
A comparison of protocols used to generate insulin-producing cell clusters from mouse embryonic stem cells. Stem Cells (2008) 0.94
Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation. Transplantation (2011) 0.93
Regulatory T cells as modulators of chronic allograft dysfunction. Curr Opin Immunol (2011) 0.93
Regulation of transplant arteriosclerosis by CD25+CD4+ T cells generated to alloantigen in vivo. Transplantation (2007) 0.93
Regenerative medicine as applied to general surgery. Ann Surg (2012) 0.92
Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur J Immunol (2011) 0.92
Induction of transplantation tolerance-the potential of regulatory T cells. Transpl Immunol (2005) 0.92
Ex vivo expanded human regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model. Transplantation (2013) 0.92
Variation in MHC expression between undifferentiated mouse ES cells and ES cell-derived insulin-producing cell clusters. Transplantation (2009) 0.91
Translating tolerogenic therapies to the clinic - where do we stand? Front Immunol (2012) 0.91
Regulatory cells in transplantation. Novartis Found Symp (2003) 0.90
Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy. Transplantation (2011) 0.90
Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med (2013) 0.90
T regulatory cells and the control of alloimmunity: from characterisation to clinical application. Curr Opin Immunol (2010) 0.90
Donor reactive regulatory T cells. Curr Opin Organ Transplant (2009) 0.90
Dependency of direct pathway CD4+ T cells on CD40-CD154 costimulation is determined by nature and microenvironment of primary contact with alloantigen. J Immunol (2004) 0.90
Tolerance: one transplant for life. Transplantation (2014) 0.89
CD25+CD4+ regulatory T cells develop in mice not only during spontaneous acceptance of liver allografts but also after acute allograft rejection. Transplantation (2006) 0.89
Analysis of the peripheral T-cell repertoire in kidney transplant patients. Eur J Immunol (2010) 0.89
Characteristics of the early immune response following transplantation of mouse ES cell derived insulin-producing cell clusters. PLoS One (2010) 0.89
Regulatory T cells in transplantation. Curr Opin Immunol (2002) 0.89
Examination of serum miRNA levels in kidney transplant recipients with acute rejection. Transplantation (2014) 0.88
Induction of transplantation tolerance through regulatory cells: from mice to men. Immunol Rev (2014) 0.88
Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4+ T-cells. Mech Ageing Dev (2010) 0.88
An investigation to assess the potential of CD25highCD4+ T cells to regulate responses to donor alloantigens in clinically stable renal transplant recipients. Transpl Int (2007) 0.87
How regenerative medicine may contribute to the achievement of an immunosuppression-free state. Transplantation (2011) 0.87
Understanding FOXP3: progress towards achieving transplantation tolerance. Transplantation (2007) 0.87
Immunologic unresponsiveness to alloantigen in vivo: a role for regulatory T cells. Immunol Rev (2011) 0.86
Alpha-1,2-mannosidase and hence N-glycosylation are required for regulatory T cell migration and allograft tolerance in mice. PLoS One (2010) 0.86
Dependency of the trans vivo delayed type hypersensitivity response on the action of regulatory T cells: implications for monitoring transplant tolerance. Transplantation (2007) 0.86
CD4+ regulatory T cells generated in vitro with IFN-{gamma} and allogeneic APC inhibit transplant arteriosclerosis. Am J Pathol (2010) 0.86
Platelet-endothelial cell adhesion molecule-1 (CD31) expression on donor endothelial cells attenuates the development of transplant arteriosclerosis. Transplantation (2002) 0.85
The where and when of T cell regulation in transplantation. Trends Immunol (2012) 0.85
Mesoangioblasts suppress T cell proliferation through IDO and PGE-2-dependent pathways. Stem Cells Dev (2012) 0.85
Regulatory T cells: hypes and limitations. Curr Opin Organ Transplant (2008) 0.85
Changing demographics and vision restrictions in civilian pilots and their clinical implications. Aviat Space Environ Med (2004) 0.84
Indirect allorecognition can play an important role in the development of transplant arteriosclerosis. Transplantation (2002) 0.84
CD4+ regulatory T cells in solid organ transplantation. Curr Opin Organ Transplant (2010) 0.84
Regulatory T cells can prevent memory CD8+ T-cell-mediated rejection following polymorphonuclear cell depletion. Eur J Immunol (2010) 0.84
Intercellular cell adhesion molecule-1 and selectin ligands in acute cardiac allograft rejection: a study on gene-deficient mouse models. J Leukoc Biol (2002) 0.83
Exhaustive differentiation of alloreactive CD8+ T cells: critical for determination of graft acceptance or rejection. Transplantation (2008) 0.83